Piece By Piece
More and more companies are using fragment-based lead design as a drug discovery strategy
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
July 21, 2008 Cover
Volume 86, Issue 29
More and more companies are using fragment-based lead design as a drug discovery strategy
Credit:
More and more companies are using fragment-based lead design as a drug discovery strategy
Preregistration for chemical regulation program settles in after a few teething problems
Obama is at odds with chemical industry on key energy and trade issues
Amyloid fibrils are hallmarks of disease but also may provide a basis for advanced nanomaterials
DSM's pharma products unit leverages its biotech strength to survive in a tough environment
New program for high-risk research is poised to award first grants, but future funding is unclear
An artist discovers her visual icon in a life-or-death medical moment